60 DEGREES PHARMACEUTICALS, INC.
tafenoquine
babesiosis
Countdown
633days
Catalyst readout · ~ Mar 31, 2028 estimated
What's at stake
A key catalyst for tafenoquine (babesiosis) is expected ~ Mar 31, 2028.
Primary source
· SEC 8-K
verified 14h ago
“The Company intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company’s randomized, placebo-controlled trial of tafenoquine in patients hospital”